![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
IN BRIEF: Nuformix narrows annual loss as develops drug assets
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.
Read more